Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

Sana revolutionizes treatments for diabetes, cancer, and autoimmune diseases. SANA has high cash burn and dilution risks. See ...

系统性红斑狼疮（SLE）是一种典型的“自作自受”的免疫系统错误，它让免疫系统误以为健康细胞是敌人，开始大举进攻。这种慢性疾病，常常给患者带来全身性的疼痛和不适，尤其是在皮肤、关节、肾脏等部位表现最为明显。

Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, ...

New research suggests the use of oral prednisone should be limited in patients with systemic lupus erythematosus with a history of recurrent pericarditis.

SLE is a multisystem autoimmune disease where periods of disease activity, often difficult to predict, can cause irreversible disease damage. This study aimed to develop a patient-centric predictive ...

In a new study, researchers explored experiences, perceptions, and health effects of a newly developed healthy lifestyle ...

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.

Members of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) group along with experienced ...

In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...